Short description
Forbius is a biopharmaceutical company that develops and designs niotherapeutics for the treatment of fibrotic diseases and cancers.
Description
Forbius (Formation Biologics) is a clinical-stage company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. The company is developing agents targeting the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways, enabling doctors to have highly active inhibitors of validated pathways that have a differentiated mechanism of action.
Forbius’ medicines are designed to radically transform patients’ lives. Their strength is utilizing their knowledge of biology and diverse protein engineering technologies to design superior inhibitors of validated biological pathways.
Forbius was founded in 2011 as a management-led spin-out from YM BioSciences, prior to YM's acquisition by Gilead.
Last funding
Noaccessforu
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Austin, Texas, United States, North America
Founded on
January 1, 2011
Exited on
August 24, 2020
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$1230 - 4560
Sign in for full access
Investors
Noaccess, Blurry Noaccess, Absolutely Noaccess, Noaccess, No Way, No Way, Noway Youcantaccess, Absolutely Noaccess, Cannot Access
Sign in for full access
Founders
Ilia A. Tikhomirov